WO2015088288A1 - 트롬빈을 이용한 줄기세포 유래 엑소좀의 생성 촉진 방법 - Google Patents
트롬빈을 이용한 줄기세포 유래 엑소좀의 생성 촉진 방법 Download PDFInfo
- Publication number
- WO2015088288A1 WO2015088288A1 PCT/KR2014/012291 KR2014012291W WO2015088288A1 WO 2015088288 A1 WO2015088288 A1 WO 2015088288A1 KR 2014012291 W KR2014012291 W KR 2014012291W WO 2015088288 A1 WO2015088288 A1 WO 2015088288A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- medium
- stem cells
- derived
- thrombin
- exosomes
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
- C12N5/0671—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/73—Hydrolases (EC 3.)
- C12N2501/734—Proteases (EC 3.4.)
Definitions
- the present invention relates to a method for promoting the production of stem cell-derived exosomes using thrombin.
- Exosomes are small vesicles with a membrane structure that are secreted from many types of cells. The diameter of the exosomes is reported to be approximately 30-100 nm. Exosomes have been observed in electron microscopy to originate in specific compartments within cells called multivesicular bodies (MVBs) and to be released and secreted out of the cell, rather than falling directly off the plasma membrane. That is, when fusion occurs between the polycystic body and the plasma membrane, the vesicles are released into the extracellular environment, which is called exosomes.
- MVBs multivesicular bodies
- exosomes are made of, but not only red blood cells, but also various immune cells and tumor cells, including B-lymphocytes, T-lymphocytes, dendritic cells, platelets, macrophages, etc.
- Stem cells are also known to produce and secrete exosomes in a living state.
- exosomes derived from stem cells contain nuclear components as well as receptors and proteins are known to play an important role in intercellular communication.
- exosomes contain relatively less animal serum than stem cells, which may exclude the risk of zoonosis due to animal serum infection. Considering the characteristics of these exosomes, cell therapy using exosomes is expected to become a new paradigm that can overcome the limitations of existing stem cell therapy.
- the present inventors completed the present invention by confirming that the production of stem cell-derived exosomes was promoted when using thrombin as a result of continuing the study on a method for increasing the production efficiency of the exosomes with excellent availability as described above.
- an object of the present invention is to provide a method for promoting the production of stem cell-derived exosomes using thrombin.
- Another object of the present invention to provide a medium composition for promoting the production of stem cell-derived exosomes containing thrombin.
- Still another object of the present invention is to provide a method for enhancing growth factor expression in stem cell-derived exosomes using thrombin.
- the present invention provides a method for promoting the production of stem cell-derived exosomes comprising the step of culturing stem cells in a medium containing thrombin.
- the present invention also provides a medium composition for promoting the production of stem cell-derived exosomes containing thrombin.
- the present invention also provides a method for enhancing growth factor expression in stem cell-derived exosomes, comprising culturing stem cells in a medium containing thrombin.
- the method according to the present invention has an excellent effect of promoting the generation of stem cell-derived exosomes, through which it is possible to obtain exosomes more efficiently than conventionally known methods, it can be usefully used in related studies.
- 1 is a diagram showing the results of observing the form of the stem cell-derived exosomes obtained using the method according to the invention through a SEM image.
- Figure 2 is a diagram showing the results of confirming the expression of the exosome markers CD63 and CD9 in the stem cell-derived exosomes obtained using the method according to the present invention.
- Figure 3 is a diagram showing the results of confirming the expression of growth factors VEGF and HGF in stem cell-derived exosomes obtained using the method according to the present invention.
- Figure 4 is a diagram showing the degree of generation of stem cell-derived exosomes according to the thrombin treatment concentration.
- FIG. 5 is a diagram showing the generation of stem cell-derived exosomes according to the treatment concentration of LPS, H 2 O 2 or thrombin.
- Figure 6 is a diagram showing the results of observing the degree of formation of endoplasmic reticulum in stem cells by thrombin treatment.
- FIG. 7 is a diagram showing the results of confirming the expression of growth factors in exosomes by thrombin treatment.
- the present invention provides a method for promoting the production of stem cell-derived exosomes comprising the step of culturing stem cells in a medium containing thrombin.
- the thrombin may be included in the medium at a concentration of 1 to 1000 U / ml, preferably at a concentration of 10 to 200 U / ml.
- the incubation time is not limited as long as the exosomes can be produced, but preferably may be performed for 12 hours to 48 hours.
- stem cells refers to cells that have the ability to differentiate into two or more different types of cells while having self-replicating ability as undifferentiated cells.
- Stem cells of the present invention may be autologous or allogeneic stem cells, may be from any type of animal, including humans and non-human mammals, and is not limited to whether the stem cells are derived from adults or embryos Do not.
- Stem cells of the present invention include embryonic stem cells or adult stem cells, preferably adult stem cells.
- the adult stem cells may be mesenchymal stem cells, human tissue-derived mesenchymal stromal cells, human tissue-derived mesenchymal stem cells, multipotent stem cells or amniotic epithelial cells, preferably mesenchymal stem cells
- the mesenchymal stem cells may be mesenchymal stem cells derived from umbilical cord, umbilical cord blood, bone marrow, fat, muscle, nerve, skin, amniotic membrane or placenta, and the like.
- “Medium” in the present invention means a composition containing essential ingredients necessary for the growth and proliferation of cells in vitro, and includes all of the culture medium for stem cells commonly used in the art, eg For example, DMEM (Dulbecco's Modified Eagle's Medium), MEM (Minimal Essential Medium), BME (Basal Medium Eagle), RPMI 1640, DMEM / F-10 (Dulbecco's Modified Eagle's Medium: Nutrient Mixture F-10), DMEM / F-12 (Dulbecco's Modified Eagle's Medium: Nutrient Mixture F-12), ⁇ -MEM ( ⁇ -Minimal essential Medium), G-MEM (Glasgow's Minimal Essential Medium), IMOC (Isocove's Modified Dulbecco's Medium), KnockOut DMEM
- a medium or an artificially synthesized medium can be used, but is not limited thereto.
- the medium of the present invention generally contains a carbon source, a nitrogen source, and
- the mesenchymal stem cells are treated with serum pre-culture medium (MEM alpha media) containing 10 to 100 U / ml of thrombin and then cultured for 24 hours to generate stem cell-derived exosomes. It was promoted and separated by ultra-fast centrifugation.
- MEM alpha media serum pre-culture medium
- the method according to the present invention has an excellent effect of promoting the generation of stem cell-derived exosomes, through which the exosomes can be obtained more efficiently than the conventionally known methods.
- the present invention also provides a medium composition for promoting the production of stem cell-derived exosomes containing thrombin.
- the thrombin may be included in the medium at a concentration of 1 to 1000 U / ml, preferably at a concentration of 10 to 200 U / ml.
- the media composition of the present invention may further include one or more known exosomes-producing substances in addition to thrombin, but is not limited thereto.
- the present invention also provides a method for enhancing growth factor expression in stem cell-derived exosomes, comprising culturing stem cells in a medium containing thrombin.
- growth factor refers to a proteinaceous physiologically active substance that promotes cell division, growth, or differentiation, for example, brain-derived neurotropic factor (BDNF), fibroblast growth factor (fibroblast growth factor (FGF), hepatocyte growth factor (HGF), nerve growth factor (NGF), vascular endothelial growth factor (VEGF), insulin-like growth factor (insulin-) like growth factor (IGF), transforming growth factor (TGF), platelet-derived growth factor (PDGF), bone-derived growth factor (BDF), colony stimulating factor (colony stimulation factor (CSF), epidermal growth factor (EGF), keratinocyte growth factor (Keratinocyte growth factor, KGF) and the like.
- BDNF brain-derived neurotropic factor
- FGF fibroblast growth factor
- HGF hepatocyte growth factor
- NGF nerve growth factor
- VEGF vascular endothelial growth factor
- IGF insulin-like growth factor
- TGF transforming growth factor
- PDGF platelet-derived growth factor
- the growth factor is preferably brain-derived neurotropic factor (BDNF), fibroblast growth factor (FGF), hepatocyte growth factor (HGF), nerve growth factor (nerve) growth factor (NGF) or vascular endothelial growth factor (VEGF), but is not limited thereto.
- BDNF brain-derived neurotropic factor
- FGF fibroblast growth factor
- HGF hepatocyte growth factor
- NGF nerve growth factor (nerve) growth factor
- VEGF vascular endothelial growth factor
- thrombin and ultracentrifuge were used. More specifically, 1 ⁇ 10 6 umbilical cord blood-derived mesenchymal stem cells were cultured in 60 mm culture dishes (orange scientific cat # 4450200) for 1 week after dispensing. After confirming that the cells were fully proliferated in the culture dish, the cells were replaced with serum-free medium (MEM alpha media) diluted with thrombin by concentration (10, 20, 50, 100 U / ml). Incubated for hours. Thereafter, the culture solution was divided into centrifuge tubes, centrifuged at 4 ° C and 10000 rpm for 30 minutes, and the supernatant was transferred to a new tube to remove cell debris. After the supernatant was ultracentrifuged again at 4 ° C., 100,000 rpm for 2 hours, the supernatant was removed and exosomes were separated (final concentration: 15 ⁇ g / ml).
- MEM alpha media serum-free medium
- Example 1 In order to check whether the exosomes separated through the procedure of Example 1 have the characteristics of the conventionally known exosomes, the following experiment was performed. First, isolated exosomes were observed through SEM images, and Western blots were used to confirm the expression of known exosome markers CD63 and CD9 (System Bioscience, Mountain View, CA, USA). In addition, after dissolving the exosome membrane using a lysis buffer, the proteins in the exosomes were separated, and the growth factors in the exosomes HGF and VEGF using the Procarta immunoassay kit (affymatrix, Santa Clara, CA, USA) The amount of was measured. The results are shown in FIGS. 1 to 3, respectively.
- the exosomes isolated through the same method as in Example 1 normally expresses the exosome markers CD63 and CD9, the presence of growth factors VEGF and HGF in the exosomes It was confirmed.
- exosomes were isolated and quantified in the same manner as in Example 1 except that LPS or H 2 O 2 was treated in the culture medium instead of thrombin. The results are shown in FIG.
- cord blood-derived mesenchymal stem cells were cultured for 6 hours in serum-free medium (MEM alpha media) diluted with 50 U / ml of thrombin. Then, the exosomes were separated in the same manner as in Example 1 and observed with an electron microscope. The results are shown in FIG.
- thrombin can promote the generation of stem cell-derived exosomes and increase the expression of growth factors in exosomes.
- the method according to the present invention has an excellent effect of promoting the generation of stem cell-derived exosomes, through which it is possible to obtain exosomes more efficiently than conventionally known methods, it can be usefully used in related studies.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (10)
- 줄기세포를 트롬빈을 포함하는 배지에서 배양하는 단계를 포함하는 줄기세포 유래 엑소좀의 생성 촉진 방법.
- 제1항에 있어서, 상기 줄기세포는 배아 줄기세포 또는 성체 줄기세포인 것을 특징으로 하는, 방법.
- 제2항에 있어서, 상기 성체 줄기세포는 중간엽 줄기세포, 인간 조직 유래 중간엽 기질세포, 인간 조직 유래 중간엽 줄기세포, 다분화능 줄기세포 및 양막 상피세포로 구성된 군에서 선택되는 1종 이상의 성체 줄기세포인 것을 특징으로 하는, 방법.
- 제3항에 있어서, 상기 중간엽 줄기세포는 제대, 제대혈, 골수, 지방, 근육, 신경, 피부, 양막 및 태반으로 구성된 군에서 선택되는 1종 이상의 조직으로부터 유래된 중간엽 줄기세포인 것을 특징으로 하는, 방법.
- 제1항에 있어서, 상기 배지는 MEM (Dulbecco's Modified Eagle's Medium), MEM (Minimal Essential Medium), BME (Basal Medium Eagle), RPMI 1640, DMEM/F-10 (Dulbecco's Modified Eagle's Medium: Nutrient Mixture F-10), DMEM/F-12 (Dulbecco's Modified Eagle's Medium: Nutrient Mixture F-12), α-MEM(α-Minimal essential Medium), G-MEM(Glasgow's Minimal Essential Medium), IMDM(Isocove's Modified Dulbecco's Medium), 및 KnockOut DMEM으로 이루어진 군에서 선택된 1종 이상의 배지인 것을 특징으로 하는, 방법.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 상기 트롬빈은 배지 내에 1 내지 1000 U/ml의 농도로 포함되는 것을 특징으로 하는, 방법.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 상기 배양은 12시간 내지 48시간 동안 수행되는 것을 특징으로 하는, 방법.
- 트롬빈을 포함하는 줄기세포 유래 엑소좀의 생성 촉진용 배지 조성물.
- 줄기세포를 트롬빈을 포함하는 배지에서 배양하는 단계를 포함하는 줄기세포 유래 엑소좀 내 성장인자 발현 증진 방법.
- 제9항에 있어서, 상기 성장인자는 뇌 유래 신경 성장인자(brain-derived neurotropic factor, BDNF), 섬유아세포 성장인자(fibroblast growth factor, FGF), 간세포 성장인자(hepatocyte growth factor, HGF), 신경 성장인자(nerve growth factor, NGF) 및 혈관상피 성장인자(vascular endothelial growth factor, VEGF)로 이루어진 군에서 선택된 1종 이상인 것을 특징으로 하는, 방법.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016539061A JP6343671B2 (ja) | 2013-12-12 | 2014-12-12 | トロンビンを利用した幹細胞由来のエキソソームの生成促進方法 |
US15/103,726 US9982233B2 (en) | 2013-12-12 | 2014-12-12 | Method for promoting generation of stem cell-derived exosome by using thrombin |
EP14869537.2A EP3081223B1 (en) | 2013-12-12 | 2014-12-12 | Method for promoting generation of stem cell-derived exosome by using thrombin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130154891 | 2013-12-12 | ||
KR10-2013-0154891 | 2013-12-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015088288A1 true WO2015088288A1 (ko) | 2015-06-18 |
Family
ID=53371507
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/012289 WO2015088286A1 (ko) | 2013-12-12 | 2014-12-12 | 줄기세포 유래 엑소좀을 유효성분으로 포함하는 뇌혈관 질환 치료용 약학적 조성물 |
PCT/KR2014/012291 WO2015088288A1 (ko) | 2013-12-12 | 2014-12-12 | 트롬빈을 이용한 줄기세포 유래 엑소좀의 생성 촉진 방법 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/012289 WO2015088286A1 (ko) | 2013-12-12 | 2014-12-12 | 줄기세포 유래 엑소좀을 유효성분으로 포함하는 뇌혈관 질환 치료용 약학적 조성물 |
Country Status (5)
Country | Link |
---|---|
US (2) | US10167448B2 (ko) |
EP (2) | EP3081222B1 (ko) |
JP (2) | JP6343671B2 (ko) |
KR (3) | KR101643825B1 (ko) |
WO (2) | WO2015088286A1 (ko) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017179840A1 (ko) * | 2016-04-15 | 2017-10-19 | 사회복지법인 삼성생명공익재단 | 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 만성폐질환 치료용 조성물 |
WO2018004237A1 (ko) * | 2016-07-01 | 2018-01-04 | 사회복지법인 삼성생명공익재단 | 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 피부상처 치료용 조성물 |
WO2018026203A1 (ko) * | 2016-08-05 | 2018-02-08 | 한양대학교 에리카산학협력단 | 지방 유래 줄기세포로부터 추출된 엑소좀을 유효성분으로 포함하는 폐 섬유증 예방 또는 치료용 조성물 |
KR101860266B1 (ko) * | 2016-07-01 | 2018-05-24 | 사회복지법인 삼성생명공익재단 | 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 피부상처 치료용 조성물 |
GB2557696A (en) * | 2016-07-11 | 2018-06-27 | National Health Res Inst | Method of producing exosomes from stem cells and use thereof |
WO2020204161A1 (ja) | 2019-04-04 | 2020-10-08 | 日産化学株式会社 | 細胞外小胞の分泌を促進するための組成物 |
CN114904043A (zh) * | 2022-04-28 | 2022-08-16 | 深圳市儿童医院 | 复合水凝胶及其制备方法和应用 |
US11833176B2 (en) * | 2017-01-16 | 2023-12-05 | Medinno Inc. | Composition for treating neonatal HIE |
EP4137140A4 (en) * | 2020-04-14 | 2024-05-22 | Samsung Life Public Welfare Foundation | COMPOSITION FOR PREVENTING OR TREATING A DIABETIC SKIN DISEASE, COMPRISING AN EXOSOME DERIVED FROM A THROMBIN-PROCESSED STEM CELL |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9919011B2 (en) * | 2014-03-18 | 2018-03-20 | Samsung Life Public Welfare Foundation | Method for treating an inflammatory brain disease comprising administering a stem cell-derived exosome |
AU2016275566B2 (en) * | 2015-06-12 | 2022-02-24 | Hudson Institute of Medical Research | A method of treatment |
KR20170085010A (ko) * | 2016-01-12 | 2017-07-21 | 주식회사 강스템바이오텍 | 고함량의 성장인자를 함유한 줄기세포 유래 엑소좀 |
WO2017188614A1 (ko) * | 2016-04-27 | 2017-11-02 | 사회복지법인 삼성생명공익재단 | 미숙아 뇌실내 출혈 치료를 위한 고효능 줄기세포 선별법 |
CN106676064A (zh) * | 2017-01-20 | 2017-05-17 | 深圳中健生物技术有限公司 | 一种脐带血间充质干细胞培养液 |
KR102144593B1 (ko) * | 2017-06-07 | 2020-08-13 | 주식회사 엑소스템텍 | 인간줄기세포 유래 엑소좀을 포함하는 세포 배양용 무혈청 배지 조성물 |
CN107349220A (zh) * | 2017-07-26 | 2017-11-17 | 深圳市泰华细胞工程有限公司 | 一种包含成纤维细胞外泌体的制剂及其用途 |
US11590175B2 (en) * | 2017-08-23 | 2023-02-28 | Merakris Therapeutics Llc | Compositions containing amniotic components and methods for preparation and use thereof |
KR101980453B1 (ko) * | 2017-11-29 | 2019-08-30 | 재단법인 아산사회복지재단 | 줄기세포 유래 엑소좀 생성 촉진용 조성물 |
EP3723773A4 (en) * | 2017-12-14 | 2021-12-22 | Mayo Foundation for Medical Education and Research | PURIFIED EXOSOME PRODUCTS, METHODS FOR THEIR MANUFACTURING AND METHOD OF USING |
CN108823159B (zh) * | 2018-07-13 | 2022-08-09 | 上海齐昔生物科技集团有限公司 | Pdgf-bb对间充质干细胞释放的外泌体的影响 |
KR20190063453A (ko) | 2019-01-15 | 2019-06-07 | 재단법인 아산사회복지재단 | 줄기세포 유래 엑소좀 생성 촉진용 조성물 |
WO2020222503A1 (ko) * | 2019-04-29 | 2020-11-05 | 사회복지법인 삼성생명공익재단 | 단백질분해효소 활성 수용체 매개 신호전달 경로의 활성을 이용한 세포외 소포의 고효율 생성능을 갖는 줄기세포의 선별방법 |
KR102268589B1 (ko) * | 2019-04-29 | 2021-06-24 | 사회복지법인 삼성생명공익재단 | 단백질분해효소 활성 수용체 매개 신호전달 경로의 활성을 이용한 세포외 소포의 고효율 생성능을 갖는 줄기세포의 선별방법 |
CN115427014A (zh) | 2019-11-28 | 2022-12-02 | 韩国科学技术研究院 | 牛奶外泌体的新用途 |
JP6967308B1 (ja) * | 2020-06-30 | 2021-11-17 | 国立大学法人高知大学 | 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤 |
CN115212232A (zh) * | 2021-04-16 | 2022-10-21 | 卓越细胞工程(香港)有限公司 | 间充质干细胞来源的外泌体治疗脑卒中的方法和组合物 |
WO2023080413A1 (ko) * | 2021-11-02 | 2023-05-11 | 주식회사 디자인셀 | 줄기세포 배양액 및 이로부터 분리된 엑소좀을 유효성분으로 포함하는 안구 질환의 예방 또는 치료용 약학적 조성물 |
KR20240019971A (ko) | 2022-08-05 | 2024-02-14 | 주식회사 엠제이바이오젠 | 엑소좀 농도 향상을 위한 조성물 및 방법 |
KR20240058028A (ko) * | 2022-10-24 | 2024-05-03 | 주식회사 디자인셀 | 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050088118A (ko) * | 2002-12-13 | 2005-09-01 | 세로고스 | 배양 배지 조성물, 배양 방법, 및 얻어진 근원세포, 및그들의 용도 |
KR20080036594A (ko) * | 2005-09-30 | 2008-04-28 | 토비시 파마슈티칼 컴패니 리미티드 | 줄기세포 및/또는 전구세포의 활성화제 |
KR20100116812A (ko) * | 2009-04-23 | 2010-11-02 | 서울대학교산학협력단 | 세포응집을 이용한 심장줄기세포의 유도, 배양 방법 및 이 방법에 의해 제조된 줄기세포 |
WO2013102219A1 (en) * | 2011-12-30 | 2013-07-04 | Amit Patel | Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060084082A1 (en) * | 1997-03-07 | 2006-04-20 | Human Genome Sciences, Inc. | 186 human secreted proteins |
FR2788780B1 (fr) | 1999-01-27 | 2001-03-30 | Ap Cells Inc | Procede de preparation de vesicules membranaires |
JP2004504011A (ja) * | 2000-04-18 | 2004-02-12 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 細胞外マトリクスポリヌクレオチド、ポリペプチドおよび抗体 |
US8537656B2 (en) | 2000-07-19 | 2013-09-17 | Ipr Licensing, Inc. | Method for compensating for multi-path of a CDMA reverse link utilizing an orthogonal channel structure |
US8518390B2 (en) * | 2003-06-27 | 2013-08-27 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells |
CA2565115A1 (en) * | 2004-05-03 | 2005-11-10 | Peter Maccallum Cancer Institute | Methods for stem cell expansion and differentiation |
US8034762B2 (en) * | 2004-09-02 | 2011-10-11 | Cognosci, Inc. | Treatment of subarachnoid hemorrhage with Apo E analogs |
WO2007049096A1 (en) * | 2005-10-25 | 2007-05-03 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | A method of expansion of endothelial progenitor cells |
KR100926975B1 (ko) * | 2007-08-01 | 2009-11-17 | 리젠프라임 주식회사 | 알지네이트로 코팅된 피브린/ha 혼합체 스캐폴드를이용한 중간엽줄기세포의 분화방법 및 연골세포의 배양방법 |
EP2329012B1 (en) * | 2008-08-20 | 2020-05-20 | Celularity, Inc. | Treatment of stroke using isolated placental cells |
JP5869342B2 (ja) * | 2008-11-19 | 2016-02-24 | アンスロジェネシス コーポレーション | 羊膜由来接着細胞 |
EP2683389B1 (en) * | 2011-03-11 | 2017-05-03 | Children's Medical Center Corporation | Methods and compositions relating to mesenchymal stem cell exosomes |
KR101405437B1 (ko) * | 2011-08-16 | 2014-06-11 | 사회복지법인 삼성생명공익재단 | 줄기세포 유래 미세소포를 포함하는 신경 생성 촉진용 조성물 |
US20140341882A1 (en) * | 2011-09-13 | 2014-11-20 | Takahiro Ochiya | Pharmaceutical product for preventing or treating alzheimer's disease |
CN104321062B (zh) * | 2012-04-03 | 2018-09-25 | 兰诺龙有限公司 | 干细胞微粒 |
US20130273011A1 (en) * | 2012-04-17 | 2013-10-17 | Medistem, Inc. | Stem cells and stem cell generated nanoparticles for treatment of inflammatory conditions and acute radiation syndrome |
KR20150059168A (ko) | 2012-07-19 | 2015-05-29 | 레뉴런 리미티드 | 줄기 세포 마이크로입자 |
US20140056842A1 (en) * | 2012-08-21 | 2014-02-27 | Jonathan Sackner-Bernstein | Cellular therapeutic approaches to traumatic brain and spinal cord injury |
-
2014
- 2014-12-12 JP JP2016539061A patent/JP6343671B2/ja active Active
- 2014-12-12 KR KR1020140179560A patent/KR101643825B1/ko active IP Right Grant
- 2014-12-12 US US15/103,663 patent/US10167448B2/en active Active
- 2014-12-12 WO PCT/KR2014/012289 patent/WO2015088286A1/ko active Application Filing
- 2014-12-12 KR KR1020140179541A patent/KR101662405B1/ko active IP Right Grant
- 2014-12-12 JP JP2016539062A patent/JP6190536B2/ja active Active
- 2014-12-12 EP EP14868825.2A patent/EP3081222B1/en active Active
- 2014-12-12 WO PCT/KR2014/012291 patent/WO2015088288A1/ko active Application Filing
- 2014-12-12 EP EP14869537.2A patent/EP3081223B1/en active Active
- 2014-12-12 US US15/103,726 patent/US9982233B2/en active Active
-
2016
- 2016-06-28 KR KR1020160080788A patent/KR101661448B1/ko active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050088118A (ko) * | 2002-12-13 | 2005-09-01 | 세로고스 | 배양 배지 조성물, 배양 방법, 및 얻어진 근원세포, 및그들의 용도 |
KR20080036594A (ko) * | 2005-09-30 | 2008-04-28 | 토비시 파마슈티칼 컴패니 리미티드 | 줄기세포 및/또는 전구세포의 활성화제 |
KR20100116812A (ko) * | 2009-04-23 | 2010-11-02 | 서울대학교산학협력단 | 세포응집을 이용한 심장줄기세포의 유도, 배양 방법 및 이 방법에 의해 제조된 줄기세포 |
WO2013102219A1 (en) * | 2011-12-30 | 2013-07-04 | Amit Patel | Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses |
Non-Patent Citations (2)
Title |
---|
CHEN, T. S. ET AL.: "Enabling a Robust Scalable Manufacturing Process for Therapeutic Exosomes through Oncogenic Immortalization of Human ESC-derived MSCs", J. TRANSL. MED., vol. 9, no. 47, 2011, pages 1 - 10, XP021097952 * |
VOGL, M. ET AL.: "Can Thrombin-activated Platelet Releasate Compensate the Age-induced Decrease in Cell Proliferation of MSC?", JOURNAL OF ORTHOPAEDIC RESEARCH, vol. 31, no. 11, 9 July 2013 (2013-07-09), pages 1786 - 1795, XP055349279 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10723997B2 (en) | 2016-04-15 | 2020-07-28 | Samsung Life Public Welfare Foundation | Composition for treating chronic pulmonary disease, comprising exosome derived from thrombin-treated stem cell |
CN109069541A (zh) * | 2016-04-15 | 2018-12-21 | 社会福祉法人三星生命公益财团 | 包含来源于凝血酶处理干细胞的外泌体的慢性肺病的治疗用组合物 |
WO2017179840A1 (ko) * | 2016-04-15 | 2017-10-19 | 사회복지법인 삼성생명공익재단 | 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 만성폐질환 치료용 조성물 |
JP2019511509A (ja) * | 2016-04-15 | 2019-04-25 | サムソン ライフ パブリック ウェルフェア ファウンデーション | トロンビン処理幹細胞に由来するエキソソームを含む慢性肺疾患治療用組成物 |
KR101843634B1 (ko) * | 2016-04-15 | 2018-03-30 | 사회복지법인 삼성생명공익재단 | 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 만성폐질환 치료용 조성물 |
KR101860266B1 (ko) * | 2016-07-01 | 2018-05-24 | 사회복지법인 삼성생명공익재단 | 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 피부상처 치료용 조성물 |
CN109641013A (zh) * | 2016-07-01 | 2019-04-16 | 社会福祉法人三星生命公益财团 | 包含凝血酶处理干细胞来源的外泌体的皮肤创伤的治疗用组合物 |
WO2018004237A1 (ko) * | 2016-07-01 | 2018-01-04 | 사회복지법인 삼성생명공익재단 | 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 피부상처 치료용 조성물 |
GB2557696A (en) * | 2016-07-11 | 2018-06-27 | National Health Res Inst | Method of producing exosomes from stem cells and use thereof |
GB2557696B (en) * | 2016-07-11 | 2022-08-10 | National Health Res Inst | Method of producing exosomes from stem cells and use thereof |
CN109562129B (zh) * | 2016-08-05 | 2023-02-17 | 胞外体干细胞株式会社 | 含有从脂肪来源的干细胞分离的外排体作为活性成分的用于预防或治疗肺纤维化的组合物 |
WO2018026203A1 (ko) * | 2016-08-05 | 2018-02-08 | 한양대학교 에리카산학협력단 | 지방 유래 줄기세포로부터 추출된 엑소좀을 유효성분으로 포함하는 폐 섬유증 예방 또는 치료용 조성물 |
JP2019527702A (ja) * | 2016-08-05 | 2019-10-03 | 株式会社エキソステムテックExostemtech Co.,Ltd. | 脂肪由来幹細胞から抽出されたエキソソームを有効成分として含む肺線維症の予防または治療用の組成物 |
KR101830290B1 (ko) * | 2016-08-05 | 2018-02-21 | 한양대학교 에리카산학협력단 | 지방 유래 줄기세포로부터 추출된 엑소좀을 유효성분으로 포함하는 폐 섬유증 예방 또는 치료용 조성물 |
CN109562129A (zh) * | 2016-08-05 | 2019-04-02 | 胞外体干细胞株式会社 | 含有从脂肪来源的干细胞提取的外排体作为活性成分的用于预防或治疗肺纤维化的组合物 |
US11833176B2 (en) * | 2017-01-16 | 2023-12-05 | Medinno Inc. | Composition for treating neonatal HIE |
WO2020204161A1 (ja) | 2019-04-04 | 2020-10-08 | 日産化学株式会社 | 細胞外小胞の分泌を促進するための組成物 |
EP4137140A4 (en) * | 2020-04-14 | 2024-05-22 | Samsung Life Public Welfare Foundation | COMPOSITION FOR PREVENTING OR TREATING A DIABETIC SKIN DISEASE, COMPRISING AN EXOSOME DERIVED FROM A THROMBIN-PROCESSED STEM CELL |
CN114904043A (zh) * | 2022-04-28 | 2022-08-16 | 深圳市儿童医院 | 复合水凝胶及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
KR101643825B1 (ko) | 2016-07-29 |
JP6190536B2 (ja) | 2017-08-30 |
KR101662405B1 (ko) | 2016-10-05 |
KR20150069554A (ko) | 2015-06-23 |
US10167448B2 (en) | 2019-01-01 |
US20160333317A1 (en) | 2016-11-17 |
WO2015088286A1 (ko) | 2015-06-18 |
EP3081222B1 (en) | 2020-04-15 |
EP3081223A4 (en) | 2017-05-17 |
EP3081222A1 (en) | 2016-10-19 |
JP6343671B2 (ja) | 2018-06-13 |
EP3081223B1 (en) | 2020-02-19 |
JP2016540014A (ja) | 2016-12-22 |
US20160310534A1 (en) | 2016-10-27 |
KR20160078946A (ko) | 2016-07-05 |
KR101661448B1 (ko) | 2016-09-30 |
EP3081222A4 (en) | 2017-08-09 |
US9982233B2 (en) | 2018-05-29 |
JP2017500033A (ja) | 2017-01-05 |
KR20150069555A (ko) | 2015-06-23 |
EP3081223A1 (en) | 2016-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015088288A1 (ko) | 트롬빈을 이용한 줄기세포 유래 엑소좀의 생성 촉진 방법 | |
WO2018226051A2 (ko) | 인간줄기세포 유래 엑소좀을 포함하는 세포 배양용 무혈청 배지 조성물 | |
WO2014181954A1 (ko) | 줄기세포의 재생능 향상을 위한 배지 조성물 및 이를 이용한 줄기세포의 배양방법 | |
WO2016047849A1 (ko) | 중간엽줄기세포-하이드로겔을 함유하는 조성물 및 이의 제조방법 | |
WO2015105356A1 (ko) | 순수 영양막층으로부터 유래된 줄기세포 및 이를 포함하는 세포치료제 | |
Zhang et al. | Therapeutic potential of non-adherent BM-derived mesenchymal stem cells in tissue regeneration | |
WO2018131779A1 (ko) | 신생아 hie 치료용 조성물 | |
WO2019107939A1 (ko) | 줄기세포 유래 엑소좀 생성 촉진용 조성물 | |
WO2019088480A2 (ko) | 에티오나마이드를 이용한 줄기세포 이동성 향상 방법 | |
WO2016068596A1 (ko) | 줄기세포 배양을 위한 배지조성물 | |
WO2019035668A9 (ko) | 중간엽 줄기세포를 포함하는 갑상선 안질환을 치료하기 위한 조성물 | |
Shanbhag et al. | Xeno-free spheroids of human gingiva-derived progenitor cells for bone tissue engineering | |
WO2013085303A1 (ko) | 개과동물 양막-유래 다분화능 줄기세포 | |
KR102173873B1 (ko) | 포자를 닮은 세포들의 계군 및 그 용도 | |
WO2013131012A1 (en) | Isolation and use of pluripotent stem cell population from adult neural crest-derived tissues | |
WO2012008733A2 (ko) | 1기 태반조직 유래 줄기세포 및 이를 함유하는 세포치료제 | |
WO2019103528A2 (ko) | 무혈청 배지 조성물 | |
WO2013119026A1 (ko) | 줄기세포를 신경세포로 분화시키는 방법 | |
US20230181647A1 (en) | Treatment of ovarian failure using regenerative cells | |
WO2011159075A2 (ko) | 2차원 배양을 이용한 성체줄기세포의 신경전구세포로의 분화방법 및 신경전구세포를 이용한 신경손상 질환 치료용 약학 조성물 | |
KR20110029591A (ko) | 제대혈 유래 간엽줄기세포로부터 신경세포 및 유모세포를 분화시키는 방법 | |
Heidari-Moghadam et al. | Role of vascular endothelial growth factor and human umbilical vein endothelial cells in designing an in vitro vascular-muscle cellular model using adipose-derived stem cells | |
US20210371814A1 (en) | Use of cistanche deserticola polysaccharides in promoting proliferation and differentiation of female germline stem cells | |
WO2012165885A1 (ko) | 조직 재생용 구조체 및 이의 제조 방법 | |
WO2018004237A1 (ko) | 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 피부상처 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14869537 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016539061 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15103726 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2014869537 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014869537 Country of ref document: EP |